Skip to main content

Current Status of Newer Carbapenems

Buy Article:

$63.00 plus tax (Refund Policy)


Objectives: Beta-lactam antibiotics represent the most commonly prescribed antibacterial agents. Since many bacteria have developed resistance to older agents, new beta-lactams have been introduced constantly. In the late 1970s, a new class of exceptionally broad-spectrum beta-lactams, the carbapenems, was identified. The carbapenems, such as the most popular imipenem and meropenem, have the widest spectra of antibacterial activity of all the beta-lactams and provide excellent coverage of many gram-negative and gram-positive aerobic and anaerobic bacteria. Despite the wide antibacterial spectrum, the carbapenems globally lack activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA) and Stenotrophomonas maltophilia.

Methods: We reviewed the principal characteristics of the novel carbapenems and their clinical implications.

Results and conclusions: We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem.

Keywords: Carbapenems; biapenem; doripenem; ertapenem; imipenem; meropenem; panipenem; tebipenem pivoxil

Document Type: Research Article


Affiliations: Clinica Malattie Infettive, Azienda Ospedaliera Universitaria San Martino di Genova, Largo R.Benzi 10, 16132 Genova, Italy.

Publication date: February 1, 2009

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more